Incretin-based therapies for type 2 diabetes: clinical utility.
Ratner
Robert
R
MedStar Research Institute, Hyattsville, MD 20783, USA. Robert.Ratner@MedStar.net
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D052216:Glucagon-Like Peptide 1